CELEX: 62013CB0210
Language: en
Date: 2013-11-14 00:00:00
Title: Case C-210/13: Order of the Court (Eighth Chamber) of 14 November 2013 (request for a preliminary ruling from the High Court of Justice (Chancery Division) — United Kingdom) — Glaxosmithkline Biologicals SA, Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG v Comptroller-General of Patents, Designs and Trade Marks (Medicinal products for human use — Supplementary protection certificate — Regulation (EC) No 469/2009 — Concepts of ‘active ingredient’ and ‘combination of active ingredients’  — Adjuvant)

7.4.2014   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 102/10
            
         Order of the Court (Eighth Chamber) of 14 November 2013 (request for a preliminary ruling from the High Court of Justice (Chancery Division) — United Kingdom) — Glaxosmithkline Biologicals SA, Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG v Comptroller-General of Patents, Designs and Trade Marks
   (Case C-210/13) (1)
   
   ((Medicinal products for human use - Supplementary protection certificate - Regulation (EC) No 469/2009 - Concepts of ‘active ingredient’ and ‘combination of active ingredients’ - Adjuvant))
   2014/C 102/13
   Language of the case: English
   
      Referring court
   
   High Court of Justice (Chancery Division)
   
      Parties to the main proceedings
   
   
      Applicants: Glaxosmithkline Biologicals SA, Glaxosmithkline Biologicals, Niederlassung der Smithkline Beecham Pharma GmbH & Co. KG
   
      Defendants: Comptroller-General of Patents, Designs and Trade Marks
   
      Re:
   
   Request for a preliminary ruling — High Court of Justice (Chancery Division) — Interpretation of Article 1(b) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products (OJ 2009 L 152, p. 1) — Concept of ‘active ingredient’ and ‘combination of active ingredients’ — Adjuvant which does not have a therapeutic effect of its own but enhances the therapeutic effect in an antigen.
   
      Operative part of the order
   
   Article 1(b) of Regulation (EC) No 469/2009 of the European Parliament and of the Council of 6 May 2009 concerning the supplementary protection certificate for medicinal products must be interpreted as meaning that, just as an adjuvant does not fall within the definition of ‘active ingredient’ within the meaning of that provision, so a combination of two substances, namely an active ingredient having therapeutic effects on its own, and an adjuvant which, while enhancing those therapeutic effects, has no therapeutic effect on its own, does not fall within the definition of ‘combination of active ingredients’ within the meaning of that provision.
   
      (1)  OJ C 189, 29.6.2013.